- Home
- BVS
BVS
Bioventus Inc.
as 04-18-2025 1:32pm EST
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 656.9M | IPO Year: | 2021 |
| Target Price: | $15.00 | AVG Volume (30 days): | 339.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.90 - $14.38 | Next Earning Date: | 05-06-2025 |
| Revenue: | $573,280,000 | Revenue Growth: | 11.89% |
| Revenue Growth (this year): | -0.48% | Revenue Growth (next year): | 6.09% |
Stock Insider Trading Activity of Bioventus Inc. (BVS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Singleton Mark Leonard | BVS | SVP & CFO | Apr 11 '25 | Sell | $7.57 | 3,875 | $29,333.75 | 141,088 | |
| D'Adamio Anthony | BVS | SVP & General Counsel | Apr 11 '25 | Sell | $7.57 | 2,958 | $22,392.06 | 131,416 | |
| Singleton Mark Leonard | BVS | SVP & CFO | Mar 24 '25 | Sell | $9.79 | 5,479 | $53,639.41 | 141,088 | |
| D'Adamio Anthony | BVS | SVP & General Counsel | Mar 17 '25 | Sell | $9.75 | 2,615 | $25,496.25 | 131,416 | |
| CHURCH KATRINA J | BVS | SVP & Chief Compliance Officer | Mar 17 '25 | Sell | $9.75 | 1,018 | $9,925.50 | 52,540 | |
| Singleton Mark Leonard | BVS | SVP & CFO | Feb 18 '25 | Sell | $10.19 | 6,498 | $66,214.62 | 141,088 | |
| D'Adamio Anthony | BVS | SVP & General Counsel | Feb 18 '25 | Sell | $10.19 | 4,380 | $44,632.20 | 131,416 | |
| CHURCH KATRINA J | BVS | SVP & Chief Compliance Officer | Feb 18 '25 | Sell | $10.19 | 1,537 | $15,662.03 | 52,540 |
Latest Bioventus Inc. News
BVS Breaking Stock News: Dive into BVS Ticker-Specific Updates for Smart Investing
Zacks
19 days ago
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now
Zacks
a month ago
Bioventus (BVS) Upgraded to Buy: Here's What You Should Know
Simply Wall St.
a month ago
Bioventus Full Year 2024 Earnings: Beats Expectations
Thomson Reuters StreetEvents
a month ago
Q4 2024 Bioventus Inc Earnings Call
GuruFocus.com
a month ago
Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ...
Zacks
a month ago
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates
MT Newswires
a month ago
Bioventus Q4 Adjusted Earnings, Revenue Rise; 2025 Outlook Set
Associated Press Finance
a month ago
Bioventus: Q4 Earnings Snapshot
Compare BVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BVS Bioventus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.